Skip to main content

EDITORIAL article

Front. Public Health
Sec. Substance Use Disorders and Behavioral Addictions
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1467826
This article is part of the Research Topic Reviews in Opioid Use Disorders View all 5 articles

Editorial: Reviews in Opioid Use Disorder

Provisionally accepted
Wendy Walwyn Wendy Walwyn 1*Kirk E. Evoy Kirk E. Evoy 2,3
  • 1 University of California, Los Angeles, Los Angeles, United States
  • 2 College of Pharmacy, The University of Texas at Austin, Austin, Texas, United States
  • 3 University Health, San Antonio, Texas, United States

The final, formatted version of the article will be published soon.

    Keywords: Naloxone, Kratom, Buprenorphine, Medications for opioid use disorder, Methadone

    Received: 21 Jul 2024; Accepted: 07 Aug 2024.

    Copyright: © 2024 Walwyn and Evoy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wendy Walwyn, University of California, Los Angeles, Los Angeles, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.